《兩會》國藥於清明:如有需要會配合本港引入新冠疫苗 正研發針對Omicron三代疫苗
正在北京出席兩會的人大代表、國藥集團董事長於清明,接受《商業電臺》書面訪問時指出,國藥新冠疫苗已在全球119個國家和地區獲批使用,若香港有需要引入國藥疫苗,會積極配合衛生署制定的疫苗接種策略,保障新冠疫苗供應。
他又稱,國藥重組蛋白新冠疫苗在阿聯酋完成一期臨牀研究,顯示疫苗安全有效,並已在阿聯酋作爲加強劑大規模接種。
至於國藥二代重組疫苗,他透露仍待有國家藥監部門審覈,期望能夠在國內獲批使用,並指二代疫苗的抗原設計,是針對變異病毒株研發,可應對多種變種病毒,而特別針對Omicron變種病毒的三代疫苗,正在研發當中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.